ProKidney Corp.

ProKidney Corp. is a clinical-stage biotechnology company developing cell therapies for chronic kidney disease (CKD). The company operates in the regenerative medicine segment, focusing on a population with limited treatment options between standard pharmacological care and dialysis or transplantation.

Its lead candidate, rilparencel (formerly REACT), is an autologous cell therapy derived from a patient's own kidney cells. The therapy is designed to preserve renal function and delay progression toward kidney failure. Rilparencel holds Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and is being evaluated in Phase 3 clinical trials for patients with Stage 3b and Stage 4 CKD associated with type 2 diabetes.

ProKidney's platform centers on selecting and expanding bioactive kidney cells, then reintroducing them via percutaneous injection into the renal cortex. The company addresses a sizable patient population, as diabetes-related CKD represents one of the leading causes of end-stage renal disease worldwide. ProKidney positions itself within the broader cell and gene therapy landscape, where autologous approaches aim to modify disease trajectory rather than manage symptoms. Its commercial focus targets nephrology practices, transplant centers and integrated health systems that manage advanced kidney disease.